Franklin Street Advisors Inc. NC Boosts Stake in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

Franklin Street Advisors Inc. NC grew its stake in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) by 293.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 48,285 shares of the biopharmaceutical company’s stock after buying an additional 36,000 shares during the quarter. Franklin Street Advisors Inc. NC owned 0.15% of Bellicum Pharmaceuticals worth $406,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Schwab Charles Investment Management Inc. raised its holdings in Bellicum Pharmaceuticals by 21.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 89,222 shares of the biopharmaceutical company’s stock worth $1,043,000 after purchasing an additional 15,556 shares during the period. Rhumbline Advisers raised its holdings in Bellicum Pharmaceuticals by 31.0% in the 2nd quarter. Rhumbline Advisers now owns 30,668 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 7,249 shares during the period. State of Wisconsin Investment Board acquired a new position in Bellicum Pharmaceuticals in the 2nd quarter worth about $234,000. Bank of New York Mellon Corp raised its holdings in Bellicum Pharmaceuticals by 28.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 122,773 shares of the biopharmaceutical company’s stock worth $1,434,000 after purchasing an additional 26,839 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in shares of Bellicum Pharmaceuticals by 1.8% during the second quarter. Principal Financial Group Inc. now owns 84,820 shares of the biopharmaceutical company’s stock valued at $991,000 after acquiring an additional 1,482 shares during the last quarter. 55.24% of the stock is owned by institutional investors and hedge funds.

In related news, CFO Alan A. Musso sold 6,206 shares of the firm’s stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $9.89, for a total transaction of $61,377.34. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Alan A. Musso sold 17,117 shares of the firm’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $9.33, for a total value of $159,701.61. Following the transaction, the chief financial officer now directly owns 31,585 shares in the company, valued at approximately $294,688.05. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,165,145 shares of company stock worth $9,696,662. Corporate insiders own 18.77% of the company’s stock.

A number of equities analysts have commented on BLCM shares. Zacks Investment Research cut Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. SunTrust Banks dropped their price target on Bellicum Pharmaceuticals to $18.00 and set a “buy” rating for the company in a research report on Wednesday. Raymond James Financial restated a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, BidaskClub lowered Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $15.43.

Shares of Bellicum Pharmaceuticals Inc (NASDAQ BLCM) traded down $0.31 during midday trading on Friday, hitting $5.56. The stock had a trading volume of 1,475,549 shares, compared to its average volume of 917,771. The firm has a market capitalization of $184.74, a PE ratio of -1.86 and a beta of 0.70. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.08 and a current ratio of 6.08. Bellicum Pharmaceuticals Inc has a twelve month low of $5.02 and a twelve month high of $15.55.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.03. The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.03 million. During the same quarter in the prior year, the business earned ($0.66) earnings per share. The firm’s quarterly revenue was up 18.2% on a year-over-year basis. sell-side analysts expect that Bellicum Pharmaceuticals Inc will post -2.93 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://baseballnewssource.com/2018/02/02/franklin-street-advisors-inc-nc-buys-36000-shares-of-bellicum-pharmaceuticals-inc-blcm/1824780.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat


Leave a Reply

 
© 2006-2018 BBNS.